title: The potential of radioimmunotherapy as a new hope for HIV patients.
abstract: HIV/AIDS remains an enormous public health burden. Advances in anti-retroviral therapy (ART) have greatly reduced mortality and morbidity but HIV remains incurable, with patients suffering numerous disease- and treatment-related side effects. Any curative strategy for HIV must selectively eliminate existing infected cells. Radioimmunotherapy (RIT) is an established clinical modality in cancer treatment and has been shown to be effective in multiple infectious diseases models. We have recently demonstrated that RIT using a gp41-targeting antibody was effective and safe in eliminating HIV-infected cells in vivo (in mice), in vitro, and ex vivo in cells from HIV patients treated with ART. In addition, there is strong evidence that this radiolabeled antibody can eliminate HIV infected cells across the blood brain barrier. We consider RIT to be the most promising backbone strategy for HIV eradication.
authors.affiliation: Departments of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.
authors.forename: Dina
authors.initials: D
authors.lastname: Tsukrov
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Dadachova
mesh_terms: D000818:Animals; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D015658:HIV Infections / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D051379:Mice; D016499:Radioimmunotherapy / Q000379:methods*; D015203:Reproducibility of Results
chemical_list: D044966:Anti-Retroviral Agents
references.citation: J Clin Oncol. 2012 May 10;30(14):1663-9
references.pmid: 22412151
references.citation: Mycopathologia. 2012 Jun;173(5-6):463-71
references.pmid: 22048869
references.citation: Clin Exp Immunol. 2011 Mar;163(3):284-95
references.pmid: 21303358
references.citation: Expert Opin Drug Deliv. 2009 Aug;6(8):771-84
references.pmid: 19566446
references.citation: HIV AIDS (Auckl). 2010;2:103-22
references.pmid: 22096389
references.citation: PLoS One. 2012;7(3):e31866
references.pmid: 22427811
references.citation: Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8
references.pmid: 22645358
references.citation: Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007120
references.pmid: 22675662
references.citation: Lancet. 2013 Jun 15;381(9883):2109-17
references.pmid: 23541541
references.citation: Lancet. 2013 Nov 2;382(9903):1464-5
references.pmid: 24182529
references.citation: PLoS Pathog. 2010 Jun 10;6(6):e1000803
references.pmid: 20548940
references.citation: PLoS Pathog. 2014 Jan;10(1):e1003872
references.pmid: 24415939
references.citation: PLoS Med. 2006 Nov;3(11):e427
references.pmid: 17090209
references.citation: Semin Nucl Med. 2009 Mar;39(2):146-53
references.pmid: 19187806
references.citation: Antimicrob Agents Chemother. 2014;58(3):1813-5
references.pmid: 24379209